Advances in understanding the regulatory functions of the nervous system have revealed neural cholinergic signaling as a key regulator of cytokine responses and inflammation. Cholinergic drugs, including the centrally acting acetylcholinesterase inhibitor, galantamine, which are in clinical use for the treatment of Alzheimer's disease and other neurodegenerative and neuropsychiatric disorders, have been rediscovered as anti-inflammatory agents. Here, we provide a timely update on this active research and clinical developments. We summarize the involvement of cholinergic mechanisms and inflammation in the pathobiology of Alzheimer's disease, Parkinson's disease, and schizophrenia, and the effectiveness of galantamine treatment. We also highlight recent findings demonstrating the effects of galantamine in preclinical and clinical settings of numerous conditions and diseases across the lifespan that are characterized by immunological, neurological, and metabolic dysfunction.

中文翻译：

---

通过用加兰他敏调节胆碱能信号来治疗整个生命周期的疾病

了解神经系统调节功能的进展表明，神经胆碱能信号是细胞因子反应和炎症的关键调节因子。胆碱能药物，包括中枢作用的乙酰胆碱酯酶抑制剂加兰他敏，在临床上用于治疗阿尔茨海默病和其他神经退行性和神经精神疾病，已被重新发现为抗炎剂。在这里，我们及时更新了这一活跃的研究和临床发展。我们总结了胆碱能机制和炎症在阿尔茨海默病、帕金森病和精神分裂症的病理生物学中的作用，以及加兰他敏治疗的有效性。